New tax inversion rules put damper on pending Pfizer-Allergan deal
An expected deal between pharmaceutical giants Pfizer and Allergan that’s expected to be worth up to $ 380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.
Modern Healthcare Breaking News
More From Around the Web
Check out these Articles
- CMS reports success in reducing overuse of antipsychotic drugs; patient adv...
- Flooding disrupts S.C. hospital workers’ commute, contaminates water ...
- Assurant Health chooses costly exit of market over full sale
- Anthem ends Q2 with higher medical expenses, unclear future with Cigna
- Drugmakers again under microscope to justify high costs
- Palmetto Health surplus booms
- What to expect when the Supreme Court takes up the Texas abortion case next...
- Cleveland Clinic to make larger tech investments
- Federal health officials approve Montana Medicaid waiver
- New administration's stance on climate change caused CDC to cancel con...
- Feds say fewer patients harmed in hospitals
- Experts divided on new head of privacy division at HHS
- CMS launches online tool to ease MACRA compliance
- CDC chief urges redoubled vigilance on Ebola diagnosis, treatment
- Anthem says Q3 profit slipped nearly 6%
- TeamHealth Q1 earnings boosted by IPC pickup and late flu season
- North Dakota nursing homes brace for state funding cutbacks
- N.Y. patient now fourth Ebola case diagnosed in U.S., preliminary test show...
- Trump's conservative pick for budget director will help guide ACA repe...